SCHEMBL1465136

SCHEMBL1465136

O=C1c2cc(Br)ccc2O[C@]12CC[C@@H](O)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 5/20 0.42
HDAC4 P56524 5/20 0.42
HDAC1 Q13547 5/20 0.42
HDAC7 Q8WUI4 5/20 0.42
HDAC2 Q92769 5/20 0.42
HDAC10 Q969S8 5/20 0.42
HDAC11 Q96DB2 5/20 0.42
HDAC8 Q9BY41 5/20 0.42
HDAC6 Q9UBN7 5/20 0.42
HDAC9 Q9UKV0 5/20 0.42
HDAC5 Q9UQL6 5/20 0.42
HSD11B1 P28845 5/20 0.41
PBRM1 Q86U86 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
PPIB P23284 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1465214 1.00 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2406130 1.00 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1465133 1.00 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL23561634 0.86 HDAC3 (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1464275 0.82 BACE1 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1464273 0.82 BACE1 (0.47) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL10604188 0.82 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL18085433 0.81 LMNA (0.45) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL1465164 0.81 HDAC3 (0.41) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL14871885 0.80 HDAC3 (0.42) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, LLC 2016-09-22 US disclosed
EP-2406240-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2015-12-23 EP disclosed
US-9212153-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2015-12-15 US disclosed
US-9045500-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2015-06-02 US disclosed
US-20150031691-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2015-01-29 US disclosed
US-8889703-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-11-18 US disclosed
EP-2801570-A1 Inhibitors of beta-secretase Vitae Pharmaceuticals, Inc. (US) 2014-11-12 EP disclosed
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2014-07-17 US disclosed
US-8633212-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-01-21 US disclosed
EP-2539322-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-01-01 EP disclosed
US-20130053377-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2013-02-28 US disclosed
EP-2539322-A1 INHIBITORS OF BETA-SECRETASE Vitae Pharmaceuticals, Inc. (US) 2013-01-02 EP disclosed
WO-2011106414-A1 INHIBITORS OF BETA-SECRETASE DILLARD LAWRENCE W (US) 2011-09-01 WO disclosed
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031691-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 HDAC3 586/4885HDAC4 781/4885HDAC1 207/4885
US-20140200223-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 HDAC3 641/4885HDAC4 940/4885HDAC1 274/4885
US-10336717-B2 Inhibitors of beta-secretase BACE1, BACE2, PSEN1 HDAC3 641/4885HDAC4 940/4885HDAC1 274/4885
US-20130053377-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 HDAC3 570/4885HDAC4 788/4885HDAC1 202/4885
US-20160272600-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 HDAC3 641/4885HDAC4 940/4885HDAC1 274/4885
US-20110071126-A1 INHIBITORS OF BETA-SECRETASE BACE1, BACE2, PSEN1 HDAC3 641/4885HDAC4 940/4885HDAC1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.